GlobeNewsWire
16 Jun 2026, 20:51 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
Grail's NHS-Galleri Trial failed to observe a statistically significant primary endpoint for Stage III-IV reduction. — Clinical trial failures for core product endpoints directly undermine the company's value proposition and commercial viability.
-0.80A class action lawsuit has been filed against Grail, Inc. alleging securities fraud or unlawful business practices. — Legal challenges and fraud allegations create systemic risk and potential financial liabilities for the company.
-0.40Which stocks this story touches
The company is facing a class action lawsuit following a failed clinical trial endpoint and a stock price drop of over 50%.
Continue reading
6 related stories
Top 3 movers · tap to explore
The company is the subject of an investigation by a law firm on behalf of investors.
The company is the subject of an investigation by a law firm on behalf of investors.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
2h ago
